Phase I safety and pharmacokinetic study of KN035, the first subcutaneously administered, novel fusion anti-PD-L1 antibody in Japanese patients with advanced solid tumors

Saved in:
Bibliographic Details
Published inJournal of Clinical Oncology Vol. 37; p. 2609
Main Authors Danming Zhu, Ni Lu, Takako Eguchi Nakajima, Ting Xu, Haolan Lu, Meng Fu, Pilin Wang, David T.L. Liu, Toshio Shimizu, Walt Cao, Ruiping Dong, Xiaoxiao Wang, John Gong, Shilin Xue, Wenlian Xu
Format Journal Article
LanguageJapanese
Published American Society of Clinical Oncology (ASCO) 20.05.2019
Online AccessGet full text
ISSN0732-183X
1527-7755
DOI10.1200/jco.2019.37.15_suppl.2609

Cover

More Information
ISSN:0732-183X
1527-7755
DOI:10.1200/jco.2019.37.15_suppl.2609